Humacyte said Symvess, its biologic vascular conduit, was featured at a Texas vascular surgery meeting as a treatment option for extremity arterial injury. The

Humacyte said Symvess, its biologic vascular conduit, was featured at a Texas vascular surgery meeting as a treatment option for extremity arterial injury. The update included no new regulatory or commercial details, underscoring the event’s clinical focus.